Gavin P. Dunn, M.D., Ph.D.

Assistant Professor
Neurological Surgery
Pathology and Immunology

Immunology Program
Molecular Cell Biology Program
Molecular Genetics and Genomics Program

  • 314 362-3570

  • 314 362-2107

  • 8057

  • gpdunn@wustl.edu

  • The immunobiology of malignant glioma with the goal of translational and clinical trial efforts in the treatment of this disease

Research Abstract:

I am a faculty member in the Department of Neurological Surgery with an appointment in the Department of Pathology and Immunology at Washington University, where I am a member of the newly established interdisciplinary Center for Human Immunology and Immunotherapy Programs. I oversee a research program focused on the immunobiology of malignant glioma with the goal of translational and clinical trial efforts in the treatment of this disease. Whereas extensive genomic profiling is uncovering tumor cell vulnerabilities across many cancer types, this paradigm has not extended to glioblastoma due, at least in part, to the tremendous heterogeneity within these tumors. In contrast to conventional targeted therapeutic approaches, immune-based strategies may be particularly well-suited to treating these tumors due to the incredible diversity of antigens recognizable by immune cells. My laboratory is focused on understanding the molecular and cellular basis of the immune response to glioblastoma in preclinical and translational settings as well as clarifying the relationships between glioma genomics and immunogenicity, an area termed cancer immunogenomics. These investigations are complemented by ongoing clinical trial efforts in this area.

Selected Publications:

Aum D, Kim D, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. 2014. Molecular and Cellular Heterogeneity: the Hallmarks of Glioblastoma. Neurosurg Focus. 2014 Dec;37(6):E11. doi: 10.3171/2014.9.FOCUS14521.

Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC. Stereotactic Laser Ablation of High-Grade Gliomas. Neurosurg Focus. Neurosurg Focus. 2014 Dec;37(6):E1. doi: 10.3171/2014.9.FOCUS14471.

Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR, Hahn WC.FRS2 is an amplified oncogene in high-grade serous ovarian cancer. Mol Cancer Res. 2014 Nov 3.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H.Emerging insights into barriers to effective brain tumor therapeutics.Front oncol. 2014 July 21; 4; 126.

Campbell AA, Cunanne ME, Dunn GP, Gray ST, Lefebvre DR. Spontaneous resorption of a penetrating orbital bone fracture fragment. Ophthal Plast Reconstr Surg. 2014 May 14.

Dunn GP and Zada G. Publication comment on "The accuracy of predicting survival in individual patients with cancer". Congress of Neurological Surgeons Neurosurgery Watch (Tumor). Feb 3 2014

Last Updated: 12/7/2015 10:14:50 AM

Back To Top

Follow us: